Abstract
BACKGROUND: Lack of consensus on how to diagnose sarcopenia has limited the ability to diagnose this condition and hindered drug development. The Sarcopenia Definitions and Outcomes Consortium (SDOC) was formed to develop evidence-based diagnostic cut-points for lean mass and/or muscle strength that identify people at increased risk of mobility disability. We describe here the proceedings of a meeting of SDOC and other experts to discuss strategic considerations in the development of evidence-based sarcopenia definition.
METHODS: Presentations and panel discussions reviewed the usefulness of sarcopenia as a biomarker, the analytical approach used by SDOC to establish cut-points, preliminary findings, and provided strategic direction to develop an evidence-based definition of sarcopenia.
RESULTS: The SDOC assembled data from 8 Epidemiologic Cohorts consisting of 18,831 participants; clinical populations from 10 randomized trials and observational studies; and 2 nationally representative cohorts. In preliminary assessments, grip strength or grip strength/body mass index (BMI) were identified as discriminators of risk for mobility disability (walking speed<0.8 m/sec), while DXA-derived lean mass measures were not good discriminators of mobility disability. Candidate definitions based on grip strength variables were associated with increased risk of mortality, falls, mobility disability and instrumental activities of daily living (IADL) disability. The prevalence of low grip strength increased with age. The attendees recommended the establishment of an International Expert panel to review a series of position statements on sarcopenia definition that are informed by the findings of the SDOC analyses and synthesis of literature.
CONCLUSIONS: International consensus on an evidence-based definition of sarcopenia is needed. Grip strength - absolute or adjusted for BMI - is an important discriminator of mobility disability and other endpoints. Additional research is needed to develop a predictive risk model that takes into account sarcopenia components as well as age, sex, and race, and comorbidities.
Original language | English |
---|---|
Pages (from-to) | 1317-1323 |
Number of pages | 7 |
Journal | The journals of gerontology. Series A : Biological sciences and medical sciences |
Volume | 75 |
Issue number | 7 |
Early online date | 13 Apr 2019 |
DOIs | |
Publication status | Published - Jul 2020 |
Bibliographical note
© The Author(s) 2019. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. For permissions, please e-mail: [email protected].Funding
Funders | Funder number |
---|---|
Centers for Disease Control and Prevention/Association of Schools of Public Health | |
NIAMS Multipurpose Arthritis and Musculoskeletal Disease Center | 5 P60 AR49465-03, 5-P60-AR30701 |
National Institute of Heart, Lung and Blood Institute | |
Netherlands Ministry of Health, Welfare and Sports, Directorate of Long-Term Care | |
Swedish Research Council grant for the Gothenburg Region of Sweden | |
National Institutes of Health | U01 AG027810, U01 AG042140, U01 AG042139, U01 AR066160, U01 AG042124, U01 AG042168, U01 AG042145, UL1 TR000128, AR049439-01A1, CUHK 4101/02M, U01 AG042143 |
Foundation for the National Institutes of Health | |
National Institute on Aging | U24AG051129, 1UO1AG051421, N01AG62106, N01AG62101, N01AG62103 |
National Heart, Lung, and Blood Institute | N01-HC-85239, N01-HC-75150, N01 HC-15103, N01-HC-25195, N01-HC-85079, HL080295, HL087652, HL103612, HL105756, N01-HC-45133, N01-HC-85080, S1734, N01 HC-55222, HHSN268201200036C, N01-HC-85085, S043, N01-HC-85086, S3486, N01-HC-85083, N01-HC-35129, N01-HC-85084, N01-HC-85081, N01-HC-85082 |
National Institute of Neurological Disorders and Stroke | AG-20098, AG-15928, AG-027058, AG-023629 |
National Institute of Arthritis and Musculoskeletal and Skin Diseases | R01AR057118, R01 AR 41398 |
National Center for Advancing Translational Sciences | |
Västra Götalandsregionen | |
Torsten Söderbergs Stiftelse | |
Petrus och Augusta Hedlunds Stiftelse | |
National Health and Medical Research Council | 301916 |
Stiftelsen för Strategisk Forskning | |
Nederlandse Organisatie voor Wetenschappelijk Onderzoek | 480-10-014 |
Lars Erik Lundbergs Stiftelse för Forskning och Utbildning | |
Vetenskapsrådet | 2006-3832 |
Chinese University of Hong Kong | 2041657 |
Göteborgs Läkaresällskap | |
Novo Nordisk Fonden | R01 AR35582, R01 AG005407, R01 AG027576, R01 AG005394, R01 AG027574, R01 AR35584, R01 AR35583 |